Enhancing [177Lu]Lu-DOTA-TATE therapeutic efficacy in vitro by combining it with metronomic chemotherapeutics
Hydroxyurea, gemcitabine and triapine all increased cell size, SSTR2A expression, and [<sup>177</sup>Lu]Lu-DOTA-TATE uptake, whilst reducing cell metabolic viability in U2OS + SSTR2A cells when compared to [<sup>177</sup>Lu]Lu-DOTA-TATE monotherapy. Further investigations could transform patient care and positively increase outcomes for patients treated with [<sup>177</sup>Lu]Lu-DOTA-TATE.
Authors
- Joke Zink (ORCID: https://orcid.org/0000-0001-6829-244X)
- Bart Cornelissen (ORCID: https://orcid.org/0000-0001-7581-3303)
- Lefteris Livieratos (ORCID: https://orcid.org/0009-0009-2156-8889)
- Edward O’Neill (ORCID: https://orcid.org/0000-0002-7987-8160)
- Julie Nonnekens (ORCID: https://orcid.org/0000-0002-9644-7522)
- Jordan Cheng (ORCID: https://orcid.org/0000-0002-9558-7603)
- Samantha Y.A. Terry (ORCID: https://orcid.org/0000-0002-6497-6681)
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- King's College London (GB)
- Guy's and St Thomas' NHS Foundation Trust (GB)
- Erasmus MC (NL)
- University of Oxford (GB)
- King's College School (GB)
- Erasmus MC Cancer Institute (NL)
Publication Details
- Journal
- EJNMMI Research
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1186/s13550-024-01135-0
- Citations
- 3
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Wellcome Trust
- National Institute for Health Research Health Protection Research Unit
- Cancer Research UK
- National Institute for Health and Care Research
- Rosetrees Trust
- Medical Research Council
- Engineering and Physical Sciences Research Council
- European Research Council
- Centre For Medical Engineering, King’s College London